Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis

Seung-Hun KANG; Hyun-Seon KIM; Myoung-Nam BAE; Jihye KIM; Ji-Yeon YOO; Kwan-Yong LEE; Dong-Gun LEE; Hee-Je KIM; Seung-Hun KANG; Hyun-Seon KIM; Myoung-Nam BAE; Jihye KIM; Ji-Yeon YOO; Kwan-Yong LEE; Dong-Gun LEE; Hee-Je KIM.
Infection and Chemotherapy ; : 49-54, 2015.
Artículo en Inglés | WPRIM | ID: wpr-221780

Documentos relacionados

  1. Novel 2-aryl-4-aryloxyquinoline-based fungistatics for Mucor circinelloides. Biological evaluation of activity, QSAR and docking study.
  2. Real world co-prescribing contraindicated drugs with fluconazole and itraconazole.
  3. Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.
  4. Antifungal Drugs TDM: Trends and Update.
  5. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
  6. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
  7. PULMONARY AND COELOMIC MYCOSES DUE TO <i>METARHIZIUM</i> AND <i>BEAUVERIA</i> SPECIES IN REPTILES.
  8. The Argentinian landscape of mycological diagnostic capacity and treatment accessibility.
  9. The cost-utility analysis of antifungal prophylaxis for invasive fungal infections in acute myeloid leukaemia patients receiving chemotherapy: a study from a middle-income country.
  10. [Antifungal susceptibility of clinically isolated invasive <i>Candida tropicalis</i> in East China from 2017 to 2021].